CONGRESS SPEAKERS

Mohamed Ahmed Abdullah is Chairman Council of Pediatric Endocrinology Fellowship Program Sudan Medical Specialization Board. President Sudan Society for Pediatric Endocrinology and Diabetes, President Sudanese Childhood Diabetes Association, and director Sudan Childhood Diabetes Center.Previously head of pediatric endocrinology King Saud University and security Forces Hospital Riyadh Saudi Arabia.

Prof. Abdullah is a member of many regional and International endocrine and diabetes societies and holds the ISPAD (International Society for Pediatric and Adolescent Diabetes) Lestradet Award for Education and Advocacy and in 2017 honored by giving the opening ceremony plenary lecture in the pediatric endocrine Societies meeting in Washington.

Prof. Abdullah has many publications in this field, reviewer to many journals, supervised many postgraduate thesis including PhDs and MDs.Main area of research interest diabetes, adrenal disorders and DSD.Has great interest in establishing pediatric endocrinology and diabetes services in limited resource settings

Dr. Basaria is an internationally recognized reproductive endocrinologist with expertise in sex-steroid biology, endocrine complications of androgen deprivation therapy in men with prostate cancer, and association of sex steroids with pain perception and pain tolerance. He is also an expert clinical trialist and has designed numerous clinical trials that are known for their novel design. Most of his clinical trials have focused on the effects of androgen replacement in men and women where he has evaluated various efficacy outcomes such as sexual function, fatigue, quality of life and physical function. He is also an expert on the risks of androgen replacement, in particular cardiometabolic disease. Dr. Basaria has over 200 peer-reviewed manuscripts, 30 book chapters and over 250 abstracts. His group was the first to report that testosterone replacement improves pain perception, sexual function and quality of life in men with opioid-induced androgen deficiency. His group was also the first to report metabolic adverse effects of androgen deprivation in men with prostate cancer. He has also conducted several epidemiological studies in collaboration with investigators from the Baltimore Longitudinal Study of Aging, the InChianti Study and the Framingham Heart Study evaluating the role of sex steroids on inflammatory markers and metabolism.

In addition to his own active research program, he is also the Associate Director of the Section of Men’s Health, Aging and Metabolism Unit at the Brigham and Women’s Hospital. In this capacity, he oversees several trials examining the effect of testosterone replacement on vitality, physical function and quality of life.

He received his MBBS from the Aga Khan University Medical School in Karachi, Pakistan; residency training at the University of Texas Health Sciences Center at Houston; and fellowship training in Endocrinology and Metabolism at the Johns Hopkins University School of Medicine in Baltimore, MD.

He serve as an Associate Editor of the Journal of Gerontology Medical Sciences and is on the editorial board of the Journal of Clinical Endocrinology and Metabolism. He lead the section on Male Reproduction on the Self-Assessment Committee of the Endocrine Society for 6 years and has contributed to the development of the Endocrine Society’s Male Androgen Deficiency Performance Improvement Module. He is also a recipient of several teaching awards and provides high-quality care for his patients in the Male Reproduction Clinic at the Brigham and Women’s Hospital.

Dr. Beshyah qualified from the Medical School of Tripoli in 1981. He started his clinical training in Tripoli till 1985 when he moved to the UK. He obtained his MRCP (UK) and MRCPI during his introductory year in Scotland under the auspices of the Royal College of Physicians and Surgeons of Glasgow. He then trained as a clinical registrar in Leicester and Bedford (1987-1989). He complete a four-year clinical research fellowship in working on the clinical and metabolic consequences of hypopituitarism and growth hormone deficiency which was the subject of his PhD thesis. After further clinical training, he was appointed consultant physician in diabetes and endocrinology in Harlow, Essex UK for 10 years. He is very keen on education and was the RCP Tutor for the last 3 years in Harlow. In 2006, Dr. Beshyah, moved to his current post in 2006. He is very keen on education and was the RCP Tutor for the last 3 years in Harlow and coordinated a busy CME program in Diabetes and Endocrinology at the SKMC, Center for Diabetes and endocrinology since his arrival. He is as associate editor of Ibnosina Journal of medicine and biomedical journal and has 39 entries in Medline in addition to numerous peer-reviewed articles and book chapters. He is the honorary treasurer of the Libyan association for diabetes and endocrinology and is a Board Member for the Gulf Chapter of the American Association of Clinical Endocrinologists. His Interests include: practical management of diabetes, endocrine disorders during pregnancy, diabetic foot and cardiovascular disorders in diabetes.

Dr. Bassam Saleh Bin-Abbas is a Consultant in the Section of Endocrinology and Diabetes, Department of Pediatrics at King Faisal Specialist Hospital and Research Center in Riyadh, Saudi Arabia. He is also a Professor of Pediatrics and Endocrinology at the Al-Faisal University. In the USA, he obtained certification at the American Board of Pediatrics after completing his residency program at Yale University in 1997 and American Board of Pediatric Endocrinology after his fellowship training at UCSF/Stanford University in 1999.

Prof Chris Byrne trained as a clinical scientist in the UK and the US, at Cardiff, Cambridge and Stanford Universities. He undertook a PhD studying liver lipid metabolism at Cambridge University. Chris was a post-doctoral fellow at Stanford University and then an MRC fellow at Cambridge University. He was appointed to the Chair of Endocrinology & Metabolism at the University of Southampton in 1999, and was also inaugural Director of the Wellcome Trust Clinical Research Facility at Southampton. He is currently Principal Investigator within the National Institute for Health Research Southampton Biomedical Research Centre. Chris undertakes research on the aetiology, pathogenesis and treatment of non alcoholic fatty liver disease (NAFLD) and specialises in caring for patients with diabetes and NAFLD. He collaborates with many researchers from around the globe, and has published over 270 publications related to metabolic syndrome and NAFLD. He was a former recipient of the Dorothy Hodgkin prize awarded by Diabetes UK, for internationally-recognised research excellence related to diabetes.

Prof. Annamaria Colao is a Full Professor of Endocrinology at the Universita' Federico II di Napoli. She studied medicine from 1977 to 1983 at the same university. She was a fellow in Pituitary Physiopathology mentored by Prof. G. Lombardi from 1981-1986. She graduated in Endocrinology and Metabolic Diseases Magna cum Laude discussing a thesis on inferior petrosal sinus sampling in 1986 and received her PhD PhD fellow in Endocrinological and Metabolic Sciences at the Department of Molecular Pathology, University "Federico II" of Naples in 1991. She was Chair of the Unit of Endocrinology of the “Federico II” University of Naples. She is also the Chair of the Health Care Provider University Hospital “Federico II” for Rare Endocrine Diseases granted from the Italian Minister of Health.

She was appointed as the Italian Coordinator of the Endocrine Reference Network for the European Commission for rare diseases ENDO-ERN. She is Chair of the Excellence European Center for Neuroendocrine Tumors granted by the European Society of Neuroendocrine Tumors and the Excellence National Center for Obesity (C.I.B.O.) granted by the Italian Society of Obesity.

She is a member of number councils such as the CNGR (Comitato Nazionale Garanti per la Ricerca) National Committee for Research from April 2012-April 2015, President of the CNGR (Comitato Nazionale Garanti per la Ricerca) National Committee for Research from April 2015-April 2016, Administrative Council of the II University of Naples (now University Vanvitelli of Campania) from 2013-2017 and the Administrative Council of the Italian Institute of Technology 2017 until present.

She has characterized scientific activities by publication of more than 800 full papers in international journals (IF 3139), more than 100 chapters in books, monografies, books; and has made 40439 citations.

Khaled Aldahmani is a Consultant Endocrinologist at Tawam Hospital in Al Ain, United Arab Emirates. He is also a Visiting Endocrinologist at New Medical Center (NMC) and Adjunct Faculty of the Department of Medicine at United Arab Emirates University. Dr. Aldahmani obtained his MBBS at the UAE University in 2006 and completed his residency in Internal Medicine at the University of British Columbia in 2011 and fellowship in Endocrinology at the Dalhousie University, Canada in 2013. Then he completed 1 year training in Pituitary Disorders and Thyroid cancer at Dalhousie University in 2014. He received board certification in Endocrinology, Diabetes and Metabolism (2013) and Internal Medicine (2011) from the American Board of Internal Medicine, as well as a certificate in Endocrinology and Metabolism (2013) and Internal Medicine (2011) from the Fellow of Royal College of Physicians and Surgeons Canada. He is a founding member and the chairman of AlAin Internal Medicine Research conference since 2015.

Dr. Aldahmani has special interest in pituitary disorders and has published the largest population based epidemiological study on sellar masses in North America. He is also a co-author of several other publications.

Aishah Ekhzaimy is a Consultant Endocrinologist and Head of the Endocrinology and Diabetes Unit at King Saud University Medical City in Riyadh, Kingdom of Saudi Arabia. She is also the current Director of the Endocrinology and Diabetes Fellowship Program in the same institute. Dr. Ekhzaimy obtained her MBBS at the UAE University in 1999 and then went on to receive further training in Canada, receiving certifications at the Royal College of Physician of Canada - Queen’s University and Canadian Board of Diabetes and Endocrinology - McGill University. She also received training certification in neuroendocrinology at University of Western Ontario-Canada and Toronto University from 2007-2008. She was certified in American Board of Internal Medicine, American Board of Diabetes and Endocrinology, and a fellow of American College of Endocrinology.

She specializes in neuroendocrinology, practicing in this area at King Saud University Medical City since January 2010, and takes special interest in managing difficult adrenal disorders, pituitary and thyroid tumors. She has publications in adrenal, diabetes and quality and research in pituitary, proteomic in thyroid disorders, thyroid and obesity.

Gordon Francis is a physician scientist and Professor of Medicine (Endocrinology and Metabolism) at the University of British Columbia in Vancouver, Canada. He has published more than 100 peer reviewed publications and book chapters primarily in the areas of lipid metabolism, high density lipoproteins, intracellular cholesterol transport and efflux, clinical lipid management, and recently the role of smooth muscle cells in foam cell formation in atherosclerotic plaque. Clinically he is Director of the Healthy Heart Program Prevention/Lipid Clinic based at St. Paul’s Hospital, one of the largest clinics for lipid disorders and cardiovascular risk reduction in Canada. He is a member of the Canadian Cardiovascular Society Guidelines panel for the management of dyslipidemia, recently advocating for the use of non-HDL-cholesterol as an alternate treatment target, and the use of nonfasting testing for screening and follow up of lipid levels. As a clinical lipidologist he has participated in many clinical trials of novel lipid-lowering therapies.

Dr. Garvey is the Butterworth Professor of Medicine in the Department of Nutrition Sciences at the University of Alabama at Birmingham. He obtained his MD degree from St. Louis University, completed residency training in Internal Medicine at Barnes Hospital, Washington University, and was a clinical fellow in Endocrinology and Metabolism at the University of Colorado Health Sciences Center and University of California, San Diego School of Medicine. He subsequently held faculty posts at UAB, University of California San Diego School of Medicine, Indiana University School of Medicine, and Medical University of South Carolina where he directed the Endocrinology Division.

Dr. Garvey has achieved international recognition for his research in the metabolic, molecular, and genetic pathogenesis of insulin resistance, Type 2 Diabetes, and obesity. His studies have involved the cellular and molecular biology of cell and animal models, metabolic investigations of human subjects on metabolic research wards, and the genetic basis of diseases in Gullah-speaking African Americans. The Garvey laboratory has made important observations regarding the pathogenesis of human insulin resistance and has been a principle contributor to our understanding of the role of the glucose transport system and glucose transporter proteins. He has identified gene families that contribute to insulin resistance in human muscle insulin using cDNA microarray, e.g., NR4A orphan nuclear receptors and the tribbles gene family, and has elucidated the role of adiponectin in cardiometabolic disease. He has contributed to the training of clinicians, basic scientists, and physician scientists. Since 1987, his laboratory has been supported by the NIH, Department of Veterans Affairs, AHA, JDFI, ADA, and other agencies.

Dr. Garvey’s career has been distinguished by a second impactful sphere of activity involving our understanding of obesity as a disease, and in advancing medical models to improve the care of patients with obesity. Dr. Garvey was the chief architect of the Complications-Centric Model for Care of the Overweight/Obese Patient. Much of his work in this area has occurred as a board member in the American Association of Clinical Endocrinologists and chair of the AACE Obesity Committee. Dr. Garvey was a lead author in the AACE Position Statement designating Obesity as a disease (Endocrine Practice 18:642, 2012); chair of the AACE Obesity Consensus Conference held in Washington DC in 2014; lead author on the evidence-based AACE obesity management guidelines (Endocr Pract. 22(7):842, 2016); and co-author of the new medical diagnostic term for obesity – Adiposity-Based Chronic Disease. This obesity treatment algorithm emphasizes the use of weight loss therapy to treat obesity-related complications as the primary goal of treatment, as opposed to reductions in BMI per se. Further, Dr. Garvey developed Cardiometabolic Disease Staging (Obesity 22:110, 2014) that allows clinicians to quantify risk for Type 2 Diabetes and cardiovascular disease mortality, when deciding upon the intensity of weight loss therapy for their patients. Thus, Dr. Garvey is a national leader in the development of medical models for the management of obesity and diabetes prevention.

Professor Desmond Johnston is the head of the Diabetes Endocrinology and Metabolism Section within the Department of Medicine. His section is involved in several clinical and laboratory based research investigating early changes in insulin secretion, insulin sensitivity and other aspects of metabolism in people predisposed to Type 2 diabetes before diabetes develops. He is also interested in the mechanisms underlying the premature vascular disease to which people with diabetes are prone and in associated metabolic disturbances.

He is also the Vice Dean for Education in the Department of Medicine at Imperial College London. His role includes responsibility for medical education and activities related to the Lee Kong Chian School of Medicine – a joint initiative between Imperial College London and Nanyang Technological University in Singapore.

He joined the St Mary’s Hospital Medical School in 1986 and is a former Chief of Service (Specialist & Elderly Medicine) in the Imperial College Healthcare NHS Trust. He is a trained clinician and is actively involved in diabetes and metabolic medicine clinics.

Mohamed Hassanein is a senior consultant in Endocrinology and Diabetes at Dubai Hospital, Dubai, UAE since 2014. He holds an Academic post of Senior Lecturer, and Associate Director for Postgraduate Diabetes Education, Cardiff University. UK since 2007and was appointed to the post of Consultant in the Department of Endocrinology and Diabetes at BCUHB, UK, in 2002. Dr. Hassanein graduated from the Faculty of Medicine, Alexandria, Egypt.

Dr. Hassanein’s main research interest is in the field of diabetes and Ramadan. He co-authored recommendations papers on this subject for the American Diabetes Association (ADA) in 2005 and 2010, and for the British Medical Journal in 2010 as well as the IDF-DAR practical guidelines, 2016. Dr. Hassanein has participated as the first author and/or a co-author in numerous studies in this field. He has published over 50 papers and has presented more than 30 oral presentations at national and international meetings.

Bryan R. Haugen, MD is Professor of Medicine and Pathology at the University of Colorado School of Medicine and a member of the University of Colorado Cancer Center. He is also Chief of the Division of Endocrinology, Metabolism & Diabetes and Director of the Thyroid Tumor Program which provides care for more than 3000 patients with thyroid cancer. He currently holds the Mary Rossick Kern and Jerome H Kern Chair in Endocrine Neoplasms Research. Dr Haugen received is BA degree in Chemistry from Saint Olaf College and medical degree from the Mayo Medical School in 1987. Internship, medical residency and endocrine fellowship were completed at the University of Colorado Health Sciences Center. Dr Haugen is a Fellow in the American College of Physicians, and member of the Association of American Physicians (AAP). Dr Haugen was President of the American Thyroid Association (ATA) 2012-2013 and Chair of the ATA thyroid nodule and differentiated cancer guidelines task force which published the guidelines in Jan 2016. He has received the Paul Starr Award from the ATA for advancements in clinical thyroidology. His current clinical interests include thyroid neoplasms, advanced thyroid cancer, thyroid dysfunction and other endocrine tumors (parathyroid, adrenal, carcinoid). Dr Haugen’s research interests include molecular studies of thyroid neoplasm diagnosis and pathophysiology as well as the study of molecular therapeutic targets. He is currently PI of 2 NCI R01 grants to study mechanisms and therapeutic targets in advanced thyroid cancer. Dr Haugen led validation of a novel molecular test (called Afirma, marketed by Veracyte, Inc) that can help avoid unnecessary surgery in certain patients with thyroid nodules. His research group is also actively studying the individual host-tumor interaction in thyroid cancer to develop novel tumor immunology tests and therapies.

Dr Haugen has had a great interest in caring for patients with thyroid cancer and helping to find better treatments and management strategies for these patients for more than 20 years.

Dr. Al Jubeh is the Chairman of Pediatrics at Sheikh Khalifa Medical City in Abu Dhabi, UAE. He is a consultant pediatric endocrinologist at SKMC since 2006. He graduated from the medical school at the University of Jordan then completed his training in pediatrics and pediatric endocrinology at the University of Texas Medical Branch in Galveston, Texas, USA. He is American Board certified in pediatrics and pediatric endocrinology. He worked as a consultant pediatric endocrinologist at Saudi Aramco Dhahran medical center until 2006.

He has several publications in peer reviewed journals and he is core faculty in the pediatric residency program at SKMC.

Dr. Al Kaabi obtained the basic medical science degree from the University of St. Andrews Scotland in 1990 and the Medical Degree from University of Manchester- England in 1993. Subsequently trained in Internal Medicine in the United Kingdom followed by Clinical Fellowship in Endocrinology and Metabolism at the University of Alberta, Edmonton, Canada where he spent two years and a half as clinical fellow at the department of Endocrinology and Metabolism and was attached to the islet cell transplant unit. In his current clinical position, he providies comprehensive ambulatory setting and consultative service in General Internal Medicine, Endocrinology, Diabetes and Metabolism. Since his return home, Dr Al Kaabi has made significant contributions into the clinical healthcare system of the UAE through his membership of the Ministry of Health National Diabetes Committee. In the community, he made the speciality of diabetes reachable and understandable by the general population to direct involvement with national guidelines preparations and awareness campaigns. He has been active in contributing to the CME, public health awareness in the community. In addition, he has been successful in organising the Annual Diabetes Workshops in the Faculty of Medicine UAE University and has been a member of the scientific committee for many local conferences, workshops and scientific meetings. . He has been elected recently as member of the board of directors of the Gulf Chapter of the American Association of Clinical Endocrinologists.

Dr Aly B. Khalil is currently a consultant endocrinologist at the Imperial London Diabetes Centre- Abu Dhabi (ICLDC) and adjunct associate Professor at the United Arab Emirates University Al Ain UAE. He graduated from the University of Marseille- France than emigrated to Canada where he received his training in Internal Medicine at Queen’s University and Endocrinology at the University of Toronto, Canada. He is an American Board Certified in Internal Medicine, Diabetes and Endocrinology, Fellow of the Royall College of Physicians and Surgeons of Canada and Fellow of the American Association of Clinical Endocrinologists.

With a special interest in the management of thyroid disorders, Dr Aly Khalil has chalked up wide ranging clinical experience, while authoring multiple publications in both areas and presenting at different regional and international meetings.

With a background firmly rooted in North America, he has held different administrative and clinical positions. He is a former President of the Ontario Diabetes Association of Canada, Founding member of the Lebanese American University and Past President of the American Association for clinical endocrinologists-Gulf Chapter.

Abdulraof Almahfouz obtained his medical degree in 1984 from the Royal College of Surgeons in Ireland. Following a two year residency in King Faisal Specialist Hospital & Reseach Center (KFSH&RC) . In 1993 Dr. Almahfouz returned to KFSH&RC after completing his postgraduate training in internal medicine and endocrinology at Harvard affiliated institutions where he held the position of Consultant Endocrinologist. During these years Dr. Almahfouz held many positions and chaired many committees such as Department of Medicine Quality Director, Endocrine fellowship director at KFSH&RC, Chairman of the Exam Committee of the Saudi council Endocrine Fellowship Program and the Section Head of Endocrinology at KFSH&RC. Dr. Almahfouz lectures at Al Faisal University and is the Endocrine Block Director of third year students as well as an active mentor and lecturer for postgraduate residents and fellows. Dr. Almahfouz is Chair of the Saudi Council Scientific Endocrine committee. He has participated as members of many scientific program for many national and regional conferences. Dr. Almahfouz is also active in public education and organized many diabetes awareness days.

Prof. Sally Marshall was educated at University of Glasgow (BSc 1975, MB 1978, MD1990).

She is currently, Professor of Diabetes, Institute of Cellular Medicine, Newcastle University and Consultant Physician, Newcastle upon Tyne Hospitals NHS Trust.

Her research interests are in diabetes and the kidney, particularly the natural history, genetics and the links with cardiovascular disease and hypertension. Lead diabetes clinician for management of cystic fibrosis related diabetes.

Helen Murphy is a Professor of Medicine (Diabetes and Antenatal Care) at the University of East Anglia and Professor of Women’s Health at Kings College London. She is also an honorary consultant physician at Cambridge University NHS Foundation Trust since 2006.

Helen runs a diabetes pregnancy research programme which aims to improve the glucose control and infant health outcomes of pregnant women with diabetes. Her research interests include improving access to preconception care, developing novel continuous glucose monitoring and artificial pancreas technologies and the role of maternal dietary intake in gestational diabetes. She supervises higher degree students from diabetes & endocrinology, clinical biochemistry and obstetrics & gynaecology. Her research is funded by the National Institute for Health Research (NIHR), Juvenile Diabetes Research Foundation (JDRF), Diabetes UK, Diabetes Research & Wellness Foundation (DRWF), and European Association for the Study of Diabetes (EASD).

Dr Ebaa Al-Ozairi is an assistant professor at Kuwait University and a specialist in diabetes and endocrinology at Mubarak Al-Kabeer hospital. She graduated from Aberdeen University (UK) and has completed her full postgraduate program in Diabetes and Endocrinology from Newcastle University, UK. She was awarded Fulbright fellowship to Joslin Diabetes Center, Harvard medical school.

Her research interest includes diabetes education, obesity, bariatric surgery, and diabetes in young people. Dr Ebaa Al-Ozairi has been accredited by the Royal College of physician as an educator and is an associate practitioner at the UK higher National Academy. Within Kuwait diabetes team, Dr Ebaa considers herself as diabetes friends.

Dr. Khalid Al Rasadi was born in Oman where he studied medicine and obtained his Medical Degree in 1998. Dr. Al Rasadi obtained his postgraduate training in Medical Biochemistry at McGill University in Canada during 2002-2006. He spent another two years in Canada, working as scientist at the Royal Victoria Hospital, McGill University, under the supervision of Prof. Jacques Genest. There he performed a number of studies on the molecular genetics of familial hypercholesterolemia and hypoalphalipoproteinemia. In that period Dr. Al Rasadi also received training at the lipid clinic of the Royal Victoria Hospital, McGill University. He was also awarded a certificate in Clinical Lipidology by the National Lipid Association in the United State in 2008.

Dr. Al Rasadi is the Head of Department of Biochemistry at the Sultan Qaboos University in Oman and head of lipid and LDL-Apheresis unit at Sultan Qaboos University Hospital. He is one of the founder members of the Oman Society of Lipid and Atherosclerosis (OSLA) and its current President. He is also the founder of the Arab States of the Gulf (GCC) Familial Hypercholesterolemia Foundation and its current President. He contributed significantly to the recognition of OSLA as an active society nationally and internationally by promoting meetings aimed at education and general awareness relating to lipid disorders and atherosclerosis. He organized conferences involving experts in the field of lipid research. His activities include public outreach meetings in Oman. International collaboration has also been initiated via OSLA. OSLA has received the IAS-Pfizer educational grant for the management of dyslipidemia in the Gulf region.

Dr. Al Rasadi is a member of national and international medical associations and a member of Oman Medical Journal and BBA-Clinical Journal editorial board. Dr Al-Rasadi is an Editor in-Chief, OSLA section in the Open Cardiovascular Medicine Journal. He is an International Atherosclerosis Society (IAS) executive board member and assessor for Fellowships. He has around 68 publications and 1 chapter book (total Citations 949, H-Index: 12).

Hussein Saadi, MD, is Chief of the Medical Subspecialties Institute at Cleveland Clinic Abu Dhabi, where he oversees nine medical subspecialties including allergy and immunology, dermatology, endocrinology, hematology and oncology, hospital medicine, infectious disease, general internal medicine, nephrology and rheumatology.

Prior to joining Cleveland Clinic Abu Dhabi, Dr. Saadi was Professor and Chairman of the Department of Internal Medicine at the Faculty of Medicine and Health Sciences, UAE University, and Consultant Endocrinologist at Tawam Hospital in Abu Dhabi. He is a former member of the Cleveland Clinic Departments of General Internal Medicine and Endocrinology staff in the US.

Dr. Saadi is a Diplomat of the American Board of Internal Medicine and the American Board of Endocrinology, Diabetes and Metabolism. He is a fellow of the American College of Physicians and the American College of Endocrinology. Dr. Saadi is also a Clinical Professor of Medicine at Cleveland Clinic Lerner College of Medicine, Case Western Reserve University. His specialty interests include diabetes mellitus, vitamin D deficiency, osteoporosis and general endocrinology.

With a medical degree from the American University of Beirut, Dr. Saadi trained in Internal Medicine and Endocrinology at Case Western Reserve University in Cleveland, Ohio, in the US.

Yousef Saleh graduated in 1991 from King Saud University in Riyadh, Saudi Arabia. He completed 3 years of residency training in Internal Medicine at King Faisal Specialist hospital and King Abdulaziz Medical City (KAMC) in Riyadh. He completed the Membership of The Royal College of Physicians (London), MRCP (U.K.) in 1994 and the Arab Board of Medicine in 1996. Subsequently he did his Fellowship Training in Endocrinology and Diabetes at The University of California, San Diego in 1997 - 1998. He re-joined KAMC as Consultant of Medicine and Endocrinology since then.

He was appointed as Assistant Professor of Medicine and Endocrinology, King Saud University for Health Sciences in 2009 and was promoted to Associate Professor in 2016.

Dr Saleh is currently the Head Division of Adult Endocrinology at the Department of Medicine, King Abdulaziz Medical City in Riyadh, Saudi Arabia.

He chaired the Saudi Board of Medicine and Medical Subspecialties at the Saudi Commission for Health Specialties between 2011 and early 2017.

Dr Saleh is currently the Vice President of the Saudi Osteoporosis Society and board member of AACE, Gulf Chapter. He is the co-establisher of the Saudi Fellowship Training Program of Diabetes in Saudi Arabia launched in March 2016.

He has more than 37 publications in peer reviewed journals in the field of diabetes and endocrinology particularly on aspects of Diabetes, Metabolic Syndrome, osteoporosis and Vitamin D in Saudi Arabia. He published the first ever Saudi National Guidelines for Osteoporosis and is the 2nd author of the Saudi Guidelines for Vitamin D.

Nasreen Al-Sayed graduated from Arabian Gulf University, college of Medicine in Bahrain. She is American Board Certified. She completed her Residency training in Internal medicine at Sinai-Grace Hospital, Wayne State University, Detroit, Michigan, USA and Fellowship training in Endocrinology and Diabetes at Cleveland Clinic Foundation, Ohio, USA. Dr. Al-Sayed is also American Board Certified in Clinical Lipidology and a fellow of American College of Physicians and fellow of American College of Endocrinologists. She has worked as assistant professor at Arabian Gulf University and is currently at Gulf Diabetes Specialist Center in Bahrain. Dr. Al-Sayed is a member of the National Lipid Association and other Diabetes and Endocrine Associations and has several research publications. She is a member of Board of Directors of the American Association of Clinical Endocrinologist, Gulf Chapter and a member of expert panel for Middle East Familial Hypercholesterolemia guidelines and FH Gulf registry. She is the National Lead investigator for FH in Bahrain.

Dr. Alsayed participated with expert panel and published first consensus recommendation for management of plasma lipid disorders for Middle East 2016. She has other several publications in the endocrine field.

Dr. Mohgah Elsheikh joined Imperial College London Diabetes Centre as a Consultant in Diabetes and Endocrinology in May 2012. Her main interests are Obesity and Reproductive Endocrinology. She is the Medical Lead for the Multidisciplinary Obesity and Metabolic surgery service, a joint collaboration between ICLDC and Healthpoint. Prior to moving to Abu Dhabi Dr Elsheikh was a Consultant Endocrinologist at the Royal Berkshire Hospital in the UK for over 10 years where she set up and was the director of a highly successful multidisciplinary bariatric and obesity service. She is equally passionate about education. She was co-founder and tutor on Reading University Certificate of Obesity Management and was involved in the development of an online primary care obesity education programme in conjunction with MD Briefcase. She has authored several papers and chapters including in the Oxford Handbook for Diabetes and Endocrinology and presented at regional and national meetings in the UK and the UAE. Finally, Dr Elsheikh is a member of the IFSO- MENAC membership and education committees.

Dr. Young is Professor of Medicine in the Mayo Clinic College of Medicine. He is a Past President of the American Endocrine Society and Past Chair of the American Board of Internal Medicine Specialty Board in Endocrinology. Dr. Young has published more than 250 articles on endocrine hypertension and adrenal and pituitary disorders. He has been the recipient of multiple education awards and has presented at more than 500 national and international meetings.

Dr. Ali S. Alzahrani is a Professor of Medicine and Endocrinology at Al Faisal University in Riyadh. Dr. Ali Zahrani obtained his Medical Degree from King Saud University in 1990. This was followed by Residency in Internal Medicine at KFSH & RC during the period 1991-1995 and Clinical and Research Fellowship at the John Hopkins School of Medicine in Baltimore, USA during the years 1995-1998. He has been a Consultant Endocrinologist at KFSH & RC since 1998. During the period 2010 to 2011, Dr. Alzahrani was a faculty member and visiting Scientist at the Division of Endocrinology and Metabolism in John Hopkins University, School of Medicine, Baltimore, United States of America. Since his return late in 2011, he has become a Scientist and Head of the Molecular Endocrinology Division in the Department of Molecular Oncology, Research Center in addition to his Consultant Endocrinology position. Most recently, he has been appointed as a Deputy Executive Director, Research Center at KFSH & RC, Jeddah.

Dr. Alzahrani is proactive in several editorial boards of famously known medical publications. He was the Editor-in Chief of the Annals of Saudi Medicine and an Editorial Board Member of the British Journal of Diabetes and Vascular Medicine. He is an Editorial Board member of the prestigious official journal of the American Thyroid Association, THYROID. Dr. Alzahrani has more than 70 peer-reviewed articles, more than ninty regional and international presentations and has conducted more than ninety lectures nationally and internationally as an invited speaker. Dr. Al Zahrani’s academic interests are clinical and molecular research in the areas of thyroid cancer and endocrine genetics.